JP2012046518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012046518A5 JP2012046518A5 JP2011193430A JP2011193430A JP2012046518A5 JP 2012046518 A5 JP2012046518 A5 JP 2012046518A5 JP 2011193430 A JP2011193430 A JP 2011193430A JP 2011193430 A JP2011193430 A JP 2011193430A JP 2012046518 A5 JP2012046518 A5 JP 2012046518A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- binding agent
- dose
- agent comprises
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011230 binding agent Substances 0.000 claims 26
- 230000037396 body weight Effects 0.000 claims 6
- 230000004044 response Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14949299P | 1999-08-18 | 1999-08-18 | |
| US60/149,492 | 1999-08-18 | ||
| US16471499P | 1999-11-11 | 1999-11-11 | |
| US60/164,714 | 1999-11-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516562A Division JP2003519096A (ja) | 1999-08-18 | 2000-08-18 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012046518A JP2012046518A (ja) | 2012-03-08 |
| JP2012046518A5 true JP2012046518A5 (enExample) | 2012-11-29 |
Family
ID=26846783
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516562A Withdrawn JP2003519096A (ja) | 1999-08-18 | 2000-08-18 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
| JP2011193430A Pending JP2012046518A (ja) | 1999-08-18 | 2011-09-06 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001516562A Withdrawn JP2003519096A (ja) | 1999-08-18 | 2000-08-18 | Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1204423B1 (enExample) |
| JP (2) | JP2003519096A (enExample) |
| AT (1) | ATE290879T1 (enExample) |
| AU (1) | AU782569B2 (enExample) |
| DE (1) | DE60018761T2 (enExample) |
| ES (1) | ES2239032T3 (enExample) |
| WO (1) | WO2001012217A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| WO2002058450A2 (en) | 2000-12-22 | 2002-08-01 | Dana-Faber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| US6627664B2 (en) * | 2001-01-30 | 2003-09-30 | Altachem Pharma Ltd. | Perylenequinones for use as sonosensitizers |
| ATE364398T1 (de) * | 2001-01-30 | 2007-07-15 | Altachem Pharma Ltd | Perylenequinone zur anwendung mit immunotherapeutischen mitteln |
| CA2441809C (en) | 2001-03-27 | 2014-07-22 | Biomira, Inc. | Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses |
| ES2304264A1 (es) * | 2001-10-26 | 2008-10-01 | Altarex Medical Corp. | Terapia de combinacion para tratar enfermedades. |
| NZ534500A (en) * | 2002-01-24 | 2007-07-27 | Barnes Jewish Hospital | Nanoparticle-based emulsions specifically targeted to integrins |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| CN101175855A (zh) * | 2005-01-28 | 2008-05-07 | 特拉维夫大学拉莫特有限公司 | 抗MUC1 α/β抗体 |
| AU2006274651B2 (en) | 2005-06-28 | 2012-09-27 | Oncothyreon Inc. | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine |
| AU2006279189B2 (en) | 2005-08-10 | 2011-08-04 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
| US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
| EP2428225A3 (en) | 2006-09-10 | 2012-05-09 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
| US7871784B2 (en) | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
| JP5773352B2 (ja) | 2008-10-28 | 2015-09-02 | 塩野義製薬株式会社 | 抗ｍｕｃ１抗体 |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US8883977B2 (en) | 2010-04-28 | 2014-11-11 | Shionogi & Co., Ltd. | MUC1 antibody |
| CA2825972A1 (en) | 2011-02-24 | 2012-08-30 | Oncothyreon Inc. | Muc1 based glycolipopeptide vaccine with adjuvant |
| BR112014004065A2 (pt) | 2011-08-22 | 2017-03-14 | Glycotope Gmbh | micro-organismos carregando um antígeno de tumor |
| JP2017009287A (ja) * | 2013-11-11 | 2017-01-12 | 東ソー株式会社 | 前立腺癌と前立腺肥大症との識別方法 |
| US10239950B2 (en) | 2014-04-28 | 2019-03-26 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof |
| WO2018138113A1 (en) * | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69329643T2 (de) * | 1992-04-13 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Gegen karzinom-assoziierte antigene gerichtete antikörper |
| JPH08505119A (ja) * | 1992-07-06 | 1996-06-04 | バイオミラ、インコーポレーテッド | 接合目的のためのタンパク質の光活性化 |
| WO1994011508A2 (en) * | 1992-11-13 | 1994-05-26 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| DE19534630A1 (de) * | 1995-09-18 | 1997-03-20 | Max Delbrueck Centrum | Monoklonale Antikörper gegen epitheliales Muzin (MUC1) |
| WO1997042973A1 (en) * | 1996-05-15 | 1997-11-20 | Altarex, Corp. | Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
| AU6017198A (en) * | 1997-01-10 | 1998-08-25 | Altarex Corp. | Substituted perylenequinones for use in photodynamic therapy |
| CA2319688A1 (en) * | 1998-02-13 | 1999-08-19 | Gunther Bastert | Specific antibodies against mammary tumor-associated mucin, method for production and use |
-
2000
- 2000-08-18 ES ES00957617T patent/ES2239032T3/es not_active Expired - Lifetime
- 2000-08-18 AT AT00957617T patent/ATE290879T1/de active IP Right Revival
- 2000-08-18 EP EP00957617A patent/EP1204423B1/en not_active Expired - Lifetime
- 2000-08-18 WO PCT/US2000/022890 patent/WO2001012217A1/en not_active Ceased
- 2000-08-18 AU AU69211/00A patent/AU782569B2/en not_active Ceased
- 2000-08-18 DE DE60018761T patent/DE60018761T2/de not_active Expired - Lifetime
- 2000-08-18 JP JP2001516562A patent/JP2003519096A/ja not_active Withdrawn
-
2011
- 2011-09-06 JP JP2011193430A patent/JP2012046518A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012046518A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2016041733A5 (enExample) | ||
| JP2016501892A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2013520442A5 (enExample) | ||
| JP2020536109A5 (enExample) | ||
| JP2013543498A5 (enExample) | ||
| ES2561495T3 (es) | Régimen de tratamiento que utiliza neratinib contra cáncer de mama | |
| JP2015534580A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2013518086A5 (enExample) | ||
| JP2012509889A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2013173775A5 (enExample) | ||
| ES2909722T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada | |
| RU2756405C2 (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| JP2017537105A5 (enExample) |